Carcinoid

14 registered clinical trials studyying Carcinoid — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. NCT07165132	RayzeBio, Inc.	Phase 1
Recruiting	Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen NCT07087054	Crinetics Pharmaceuticals Inc.	Phase 3
Completed	Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome NCT05361668	Crinetics Pharmaceuticals Inc.	Phase 2
Recruiting	Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Fo NCT05477576	RayzeBio, Inc.	Phase 3
Withdrawn	Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers NCT03623984	University of Alabama at Birmingham	EARLY_Phase 1
Active Not Recruiting	DOTATOC PET/CT for Imaging NET Patients NCT03583528	British Columbia Cancer Agency	—
Enrolling By Invitation	RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide NCT02270567	Wren Laboratories LLC	—
Unknown	68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors NCT02038738	Ochsner Health System	Phase 1 / Phase 2
Completed	Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) NCT01327612	Amgen	Phase 2
Terminated	Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies NCT01165658	M.D. Anderson Cancer Center	Phase 1
Recruiting	Natural History of Familial Carcinoid Tumor NCT00646022	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—
Completed	ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoi NCT00339131	Molecular Insight Pharmaceuticals, Inc.	Phase 1
Unknown	Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features NCT00314925	Neotropix	Phase 1
Completed	EPO906 in Carcinoid and Other Neuroendocrine Tumors NCT00050349	Novartis Pharmaceuticals	Phase 2